Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.06 USD
-0.03 (-2.75%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.06 0.00 (0.00%) 7:46 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 21 - 40 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology -ASCO 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
1Q23 Results; Lower Xpovio Sales Despite Higher Demand Due to Patient Assistance Program; Lower PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Patient Assistance Doesn''t Assist Revenues in 2023
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor Movin'' on Up to Phase 3 in 1L MF and Ditches 2L
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Data Update From Phase 1 XPORT-MF-034 Study of Xpovio in Treatment-Naive MF Patients; Phase 3 to Begin 2Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Full Marketing Authorization From the U.K. MHRA for SVd in MM Patients With at Least One Prior Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q22 Results; Two Pivotal Xpovio Studies Ongoing, and Another in MF Could Initiate in 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Preliminary 4Q22 and FY22 Revenues Announced; Lower PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
XPOVIO Sales at Low End of Guidance; Can Earlier Line MM Lift Growth?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Updated Phase 1 Data for Xpovio in Treatment-Naive Patients Presented at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology- ASH Day 3 Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D